大环内酯类药物治疗慢性阻塞性肺疾病现状及启示

Current status and inspiration on macrolides in the therapy of chronic obstructive pulmonary disease

慢性阻塞性肺疾病(简称慢阻肺)主要与烟草烟雾等有害气体及有害颗粒的慢性炎症反应增强有关,如何早期、有效地抗炎治疗是目前慢阻肺治疗的难点。现有的抗炎方法不能满足临床需求,亟待新的抗炎药物和治疗靶点。大环内酯类药物作为抗炎药物已应用于多种气道慢性炎症性疾病,且目前在慢阻肺的应用研究有很大进展,有希望成为今后慢阻肺的有效抗炎治疗药物之一。

Chronic obstructive pulmonary disease（COPD） is associated with an enhanced chronic inflammatory response to noxious particles or gases in the airways and the lung. Difficulties exist in the early and effective anti-inflammatory strategies. Present anti-inflammatory drugs are not enough to satisfy clinical requirement, so novel antibiotics and therapeutic targets are expected. Besides the antibacterial effects, macrolides also have immunomodulatory and anti-inflammatory effects. Macrolides have been applied in the treatment of multiple chronic inflammatory airway diseases and great progress has been made in therapy of COPD. Thus, macrolide may become a new and effective anti-inflammatory drug in treatment of COPD.